Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-64042056 in Preclinical Alzheimer's Disease
NCT06544616Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2024
- Primary completion
- Dec 2026
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines
- Countries
- 9
01
Overview
A Phase 2 trial of ACI-35.030 in Alzheimer's disease (AD), sponsored by Janssen Pharmaceutical. Started Jul 2024; status: active, not recruiting.
02
Drugs
ACI-35.030
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06544616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06544616.